Biomunex Pharmaceuticals is at the forefront of developing innovative immuno-therapeutics for oncology, leveraging its proprietary BiXAb® platform, which specializes in bi- and multi-specific antibodies. This platform allows for the rapid and efficient generation of antibodies by utilizing a "Plug-and-Play" system that can create new antibody compositions in less than six weeks. The BiXAb technology is designed to incorporate the Fabs from any pair of monoclonal antibodies, ensuring excellent pairing and robust manufacturability. This unique approach not only enhances the speed of development but also maintains the drug-like properties of the antibodies, such as high binding affinities and low immunogenicity, making it a leading solution in the bispecific antibody field.

A significant focus of Biomunex's research is the development of BiXAb-MAIT engagers, which aim to redirect Mucosal Associated Invariant T (MAIT) cells to target and kill cancer cells, particularly in solid tumors. This innovative strategy addresses the limitations of traditional CD3-based T-cell engagers, such as cytokine release syndrome, by selectively activating MAIT cells without triggering other T-cell subsets. The BiXAb-MAIT engagers are expected to provide a larger therapeutic window and improved efficacy in treating various cancers, including hematological malignancies. Biomunex's commitment to advancing these groundbreaking therapies is underscored by its collaborations with leading research institutions, positioning the company as a pioneer in the field of cancer immunotherapy.

France

BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies.
Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy.

Biomunex Pharmaceuticals

Company Details